phosphorylcholine has been researched along with Ductus Arteriosus, Patent in 4 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Ductus Arteriosus, Patent: A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of surfactant administration for respiratory distress syndrome (RDS) on indomethacin (INDO) pharmacodynamics and dosing requirements for patent ductus arteriosus (PDA) closure and renal toxicity was evaluated." | 1.36 | Indomethacin pharmacodynamics are altered by surfactant: a possible challenge to current indomethacin dosing guidelines created before surfactant availability. ( Carlos, RQ; Davonzo, C; Dimaguila, MA; Gal, P; McPherson, C; Ransom, JL; Smith, M; Wimmer, JE, 2010) |
| "Pulmonary hemorrhage was defined by an onset of bright red blood from the endotracheal tube in quantities that resulted in increased ventilatory support and a new infiltrate on a chest radiograph." | 1.29 | Pulmonary hemorrhage risk in infants with a clinically diagnosed patent ductus arteriosus: a retrospective cohort study. ( Buck, R; Garland, J; Weinberg, M, 1994) |
| "A haemodynamically significant patent ductus arteriosus was clinically evident significantly earlier in babies who had received Survanta (mean age 1." | 1.29 | Differences in immediate and short-term outcome of premature neonates treated with two types of exogenous surfactant preparation. ( Malathi, I; Ng, KC, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McPherson, C | 1 |
| Gal, P | 1 |
| Ransom, JL | 1 |
| Carlos, RQ | 1 |
| Dimaguila, MA | 1 |
| Smith, M | 1 |
| Davonzo, C | 1 |
| Wimmer, JE | 1 |
| Garland, J | 1 |
| Buck, R | 1 |
| Weinberg, M | 1 |
| Malathi, I | 1 |
| Ng, KC | 1 |
| Stevenson, D | 1 |
| Walther, F | 1 |
| Long, W | 1 |
| Sell, M | 1 |
| Pauly, T | 1 |
| Gong, A | 1 |
| Easa, D | 1 |
| Pramanik, A | 1 |
| LeBlanc, M | 1 |
| Anday, E | 1 |
1 trial available for phosphorylcholine and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. The American Exosurf Neonatal Study Group I.
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Double-Blind Method; Drug Combinations; Ductus Arte | 1992 |
3 other studies available for phosphorylcholine and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Indomethacin pharmacodynamics are altered by surfactant: a possible challenge to current indomethacin dosing guidelines created before surfactant availability.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Biological Products; Coho | 2010 |
Pulmonary hemorrhage risk in infants with a clinically diagnosed patent ductus arteriosus: a retrospective cohort study.
Topics: Cohort Studies; Drug Combinations; Ductus Arteriosus, Patent; Fatty Alcohols; Female; Hemorrhage; Hu | 1994 |
Differences in immediate and short-term outcome of premature neonates treated with two types of exogenous surfactant preparation.
Topics: Biological Products; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Drug Combinations; Ductus Arte | 1995 |